LRIG1 and cancer: Subsequent genomic, histological and functional studies have demonstrated downregulation and tumor-inhibitory effects of LRIG1, and correlated LRIG1 to favorable clinical outcomes, in several human cancers including breast, bladder, colon, cervical, and non-small-cell lung cancers and gliomas6–14.